Driving a car at 40 mph, you see a child dart into the street. You hit the brakes. Disaster averted. But how did your eyes detect that movement? It’s a question that has confounded scientists. Now, studying mice, researchers at Washington University Sc…
Uncategorized
Avenova Successfully Brings Relief to Patient with Challenging and Painful Eyelid Disease
DELRAY BEACH, Fla.–(BUSINESS WIRE)–Delray Eye Associates announced today that Delray ophthalmologist Steven I Rosenfeld, MD, FACS, who specializes in medical and surgical treatments of corneal conditions, infectious and inflammatory eye diseases, has written an article in Ophthalmic Professional describing how a new eyelid and lash hygiene product called Avenova™ successfully managed the eyelid disease of a particularly challenging patient. As Dr. Rosenfeld describes, the 68-year-old man had
Bayer HealthCare, Johns Hopkins University to jointly develop new ophthalmic therapies targeting retinal diseases
The Johns Hopkins University and Bayer HealthCare have entered into a five-year collaboration agreement to jointly develop new ophthalmic therapies targeting retinal diseases. The goal of the strategic research alliance is to accelerate the translation…
Avalanche Eye Gene Therapy Meets Safety Goal
Avalanche Biotechnologies Inc’s experimental gene therapy for a leading cause of blindness met its primary safety goal in a small mid-stage trial, while staving off vision loss. Reuters Health Information
Uncategorized
FDA warns anti-seizure drug may cause skin discoloration, vision loss
The FDA has announced that there are potential vision loss risks because of pigment changes in the retina and possible skin discoloration for patients treated with the anti-seizure drug Potiga, according to reviews of additional safety data.By followin…
Uncategorized
Clearside, FDA agree on path forward for uveitic macular edema treatment
Clearside Biomedical and the FDA have agreed on the overall development plan for CLS-TA, triamcinolone acetonide injectable suspension, for treatment of macular edema associated with non-infectious uveitis, according to a company press release. “The Agency has accepted our proposed plan to conduct one randomized, double-masked, sham-controlled phase 3 clinical study along with appropriate literature supporting this indication as part of the requirements for a potential 505(b)(2) NDA submission,” Daniel H. White, president and CEO of Clearside, said in the release.